Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series

Overview of attention for article published in OncoTargets and therapy, September 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

So far, Altmetric has seen 1 news story.

Clinical Challenges > SABCS: HER2+ Emergence of targeted anti-HER2 therapies has improved the outlook for these patients by…